May 24, 2022 / 02:00PM GMT
Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst
Good morning, and thanks for joining us to have a conversation with Tim Wright, CEO; and Bob Stein, Executive Vice President, R&D of MiMedx. MiMedx is a leader in wound care and regenerative medicine. The company currently commercializes a portfolio of amniotic tissue products, bringing in nearly $250 million in annual revenues and has a portfolio of products for novel indications that could enter the market over the next 3 years.
To talk about the company's strategy for 2022 and beyond, I welcome Tim Wright and Bob Stein to this fireside chat with me. Tim and Bob, glad to see you both, and I appreciate you accepting our invitation to talk to our audience today.
Questions and Answers:
Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare AnalystSo let us start talking through some of your thoughts on the commercial growth in 2022 and then about
Trustpilot
